COPENHAGEN, Denmark; December 29, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that it will discontinue further clinical development of acasunlimab. This decision was made as part of Genmab’s ...
Highest priority programs – BEAM-101 and ESCAPE for sickle cell disease and BEAM-302 for alpha-1 antitrypsin deficiency – expected to provide foundation for meaningful value creation Company to ...
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to ...
Prioritizing metastatic non-small cell lung cancer launch and focusing research and development activities in areas of greatest anticipated value creation Expected reduction in residual operating ...
Prioritization and restructuring results in headcount reduction of approximately 15% SEATTLE, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating ...
SOUTH PLAINFIELD, N.J., Sept. 28, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (PTCT) announced today further strategic prioritization and associated workforce reduction. The portfolio prioritization ...
Genmab to discontinue clinical development of acasunlimab following a portfolio review Decision reflects prioritization of higher‑impact opportunities across Genmab’s late‑stage pipeline and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results